	US 12,221,466 B2
	TCR, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining TCR
Shiping Jiao, Jiangsu (CN)
Assigned to Shiping Jiao, Nanjing (CN); and Kshihua (Nanjing) Biotechnology Co., Ltd, Nanjing (CN)
Filed by Shiping Jiao, Jiangsu (CN); and Keshihua (Nanjing) Biotechnology Co., Ltd, Jiangsu (CN)
Filed on May 9, 2022, as Appl. No. 17/739,317.
Claims priority of application No. 202110258515 (CN), filed on Mar. 9, 2021.
Prior Publication US 2023/0028781 A1, Jan. 26, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01)

CPC C07K 14/7051 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4632 (2023.05); A61K 39/464486 (2023.05); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/55 (2023.05)]

17 Claims

1. A T cell receptor (TCR), comprising

a TCRα polypeptide comprising CDRα1 having an amino acid sequence comprising SEQ ID No: 64, CDRα2 having an amino acid sequence comprising SEQ ID No:94, and CDRα3 having an amino acid sequence comprising SEQ ID No: 124; and

a TCRβ polypeptide comprising CDRβ1 having an amino acid sequence comprising SEQ ID No: 154, CDRβ2 having an amino acid sequence comprising SEQ ID No: 184, and CDRβ3 having an amino acid sequence comprising SEQ ID No: 214,

wherein the T cell receptor (TCR) further comprises a humanized C domain and/or a murine C domain and/or a modified humanized C domain, wherein the humanized C domain comprises SEQ ID No: 243 or 244, the murine C domain comprises SEQ ID No: 245 or 246, and the modified humanized C domain comprises SEQ ID No: 247 or 248.